Maze Therapeutics (MAZE) EBITDA (2024 - 2026)

Maze Therapeutics has reported EBITDA for 3 years, with the latest figure at -$26.6 million in Q1 2026.

• Quarterly EBITDA rose 24.99% year-over-year to -$26.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$134.1 million (down 367.04% YoY) and the FY2025 annual result came in at -$142.9 million, down 348.15% from the prior year.
• EBITDA rose to -$26.6 million in Q1 2026 per MAZE's latest filing, from -$38.1 million in the prior quarter.
• Over five years, EBITDA peaked at $139.6 million in Q2 2024 and troughed at -$38.1 million in Q4 2025.
• A 3-year average of -$12.4 million and a median of -$29.7 million in 2024 frame the typical range for EBITDA.
• The sharpest annual moves came in 2025 and 2026: EBITDA sank 126.14% in 2025, then rose 24.99% in 2026.
• Over 3 years, EBITDA stood at -$29.7 million in 2024, then retreated by 28.03% to -$38.1 million in 2025, then soared by 30.23% to -$26.6 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$26.6 million, -$38.1 million, and -$33.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.